IDEAS home Printed from https://ideas.repec.org/a/bla/biomet/v65y2009i3p866-875.html
   My bibliography  Save this article

A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents

Author

Listed:
  • Guosheng Yin
  • Ying Yuan

Abstract

No abstract is available for this item.

Suggested Citation

  • Guosheng Yin & Ying Yuan, 2009. "A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents," Biometrics, The International Biometric Society, vol. 65(3), pages 866-875, September.
    • Handle: RePEc:bla:biomet:v:65:y:2009:i:3:p:866-875
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1111/j.1541-0420.2008.01119.x
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Z. Yuan & R. Chappell & H. Bailey, 2007. "The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi-Likelihood Approach," Biometrics, The International Biometric Society, vol. 63(1), pages 173-179, March.
    2. Xuelin Huang & Swati Biswas & Yasuhiro Oki & Jean-Pierre Issa & Donald A. Berry, 2007. "A Parallel Phase I/II Clinical Trial Design for Combination Therapies," Biometrics, The International Biometric Society, vol. 63(2), pages 429-436, June.
    3. Mauro Gasparini & Jeffrey Eisele, 2000. "A Curve-Free Method for Phase I Clinical Trials," Biometrics, The International Biometric Society, vol. 56(2), pages 609-615, June.
    4. Linda M. Haines & Inna Perevozskaya & William F. Rosenberger, 2003. "Bayesian Optimal Designs for Phase I Clinical Trials," Biometrics, The International Biometric Society, vol. 59(3), pages 591-600, September.
    5. Kai Wang & Anastasia Ivanova, 2005. "Two-Dimensional Dose Finding in Discrete Dose Space," Biometrics, The International Biometric Society, vol. 61(1), pages 217-222, March.
    6. Peter F. Thall & Randall E. Millikan & Peter Mueller & Sang-Joon Lee, 2003. "Dose-Finding with Two Agents in Phase I Oncology Trials," Biometrics, The International Biometric Society, vol. 59(3), pages 487-496, September.
    7. Mario Stylianou & Nancy Flournoy, 2002. "Dose Finding Using the Biased Coin Up-and-Down Design and Isotonic Regression," Biometrics, The International Biometric Society, vol. 58(1), pages 171-177, March.
    8. Mark R. Conaway & Stephanie Dunbar & Shyamal D. Peddada, 2004. "Designs for Single- or Multiple-Agent Phase I Trials," Biometrics, The International Biometric Society, vol. 60(3), pages 661-669, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Koichi Hashizume & Jun Tshuchida & Takashi Sozu, 2022. "Flexible use of copula‐type model for dose‐finding in drug combination clinical trials," Biometrics, The International Biometric Society, vol. 78(4), pages 1651-1661, December.
    2. Hengzhen Huang & Hong†Bin Fang & Ming T. Tan, 2018. "Experimental design for multi†drug combination studies using signaling networks," Biometrics, The International Biometric Society, vol. 74(2), pages 538-547, June.
    3. Márcio A. Diniz & Sungjin Kim & Mourad Tighiouart, 2020. "A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades," Stats, MDPI, vol. 3(3), pages 1-18, July.
    4. Nolan A. Wages & Mark R. Conaway & John O'Quigley, 2011. "Continual Reassessment Method for Partial Ordering," Biometrics, The International Biometric Society, vol. 67(4), pages 1555-1563, December.
    5. Beibei Guo & Elizabeth Garrett‐Mayer & Suyu Liu, 2021. "A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 70(5), pages 1210-1229, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Guosheng Yin & Ying Yuan, 2009. "Bayesian dose finding in oncology for drug combinations by copula regression," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(2), pages 211-224, May.
    2. Chunyan Cai & Ying Yuan & Yuan Ji, 2014. "A Bayesian dose finding design for oncology clinical trials of combinational biological agents," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 63(1), pages 159-173, January.
    3. Nolan A. Wages & Mark R. Conaway & John O'Quigley, 2011. "Continual Reassessment Method for Partial Ordering," Biometrics, The International Biometric Society, vol. 67(4), pages 1555-1563, December.
    4. Beibei Guo & Suyu Liu, 2018. "Optimal Benchmark for Evaluating Drug-Combination Dose-Finding Clinical Trials," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 10(1), pages 184-201, April.
    5. Xuelin Huang & Swati Biswas & Yasuhiro Oki & Jean-Pierre Issa & Donald A. Berry, 2007. "A Parallel Phase I/II Clinical Trial Design for Combination Therapies," Biometrics, The International Biometric Society, vol. 63(2), pages 429-436, June.
    6. Márcio A. Diniz & Sungjin Kim & Mourad Tighiouart, 2020. "A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades," Stats, MDPI, vol. 3(3), pages 1-18, July.
    7. Thomas M. Braun & Shufang Wang, 2010. "A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents," Biometrics, The International Biometric Society, vol. 66(3), pages 805-812, September.
    8. Nadine Houede & Peter F. Thall & Hoang Nguyen & Xavier Paoletti & Andrew Kramar, 2010. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials," Biometrics, The International Biometric Society, vol. 66(2), pages 532-540, June.
    9. Mark R. Conaway & Stephanie Dunbar & Shyamal D. Peddada, 2004. "Designs for Single- or Multiple-Agent Phase I Trials," Biometrics, The International Biometric Society, vol. 60(3), pages 661-669, September.
    10. Sean M. Devlin & Alexia Iasonos & John O’Quigley, 2021. "Phase I clinical trials in adoptive T‐cell therapies," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 70(4), pages 815-834, August.
    11. Daniel R. Cavagnaro & Richard Gonzalez & Jay I. Myung & Mark A. Pitt, 2013. "Optimal Decision Stimuli for Risky Choice Experiments: An Adaptive Approach," Management Science, INFORMS, vol. 59(2), pages 358-375, February.
    12. Linda M. Haines & Inna Perevozskaya & William F. Rosenberger, 2003. "Bayesian Optimal Designs for Phase I Clinical Trials," Biometrics, The International Biometric Society, vol. 59(3), pages 591-600, September.
    13. Azriel, David, 2014. "Optimal sequential designs in phase I studies," Computational Statistics & Data Analysis, Elsevier, vol. 71(C), pages 288-297.
    14. Tian, Guo-Liang & Ng, Kai Wang & Tan, Ming, 2008. "EM-type algorithms for computing restricted MLEs in multivariate normal distributions and multivariate t-distributions," Computational Statistics & Data Analysis, Elsevier, vol. 52(10), pages 4768-4778, June.
    15. B. Nebiyou Bekele & Yisheng Li & Yuan Ji, 2010. "Risk-Group-Specific Dose Finding Based on an Average Toxicity Score," Biometrics, The International Biometric Society, vol. 66(2), pages 541-548, June.
    16. Oron Assaf P. & Azriel David & Hoff Peter D., 2011. "Dose-Finding Designs: The Role of Convergence Properties," The International Journal of Biostatistics, De Gruyter, vol. 7(1), pages 1-17, October.
    17. Xiaobin Yang & Keying Ye, 2012. "A Phase I Dose-_finding Study Based on Polychotomous Toxicity Responses Toxicity issue is always a main concern in phase I study and it is commonly categorized to multiple grades. In this study, the c," Working Papers 0004, College of Business, University of Texas at San Antonio.
    18. B. Nebiyou Bekele & Yu Shen, 2005. "A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-Finding Trial," Biometrics, The International Biometric Society, vol. 61(2), pages 343-354, June.
    19. Alessandra Giovagnoli, 2021. "The Bayesian Design of Adaptive Clinical Trials," IJERPH, MDPI, vol. 18(2), pages 1-15, January.
    20. Anastasia Ivanova & Se Hee Kim, 2009. "Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach," Biometrics, The International Biometric Society, vol. 65(1), pages 307-315, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:biomet:v:65:y:2009:i:3:p:866-875. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0006-341X .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.